<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801329</url>
  </required_header>
  <id_info>
    <org_study_id>B3461080</org_study_id>
    <secondary_id>Vyndamax PMS</secondary_id>
    <nct_id>NCT04801329</nct_id>
  </id_info>
  <brief_title>Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy</brief_title>
  <official_title>KOREAN POST-MARKETING SURVEILLANCE VYNDAMAX (Registered) CAPSULES FOR THE TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This non-interventioal study will be performed by design of post-marketing surveillance (PMS)&#xD;
      as an additional pharmacovigilance activity of the Risk Management Plan (RMP) for Vyndamax®&#xD;
      Capsules, which is required by the Ministry of Food and Drug Safety (MFDS) according to the&#xD;
      local regulation. This post-marketing surveillance will investigate the safety and&#xD;
      effectiveness of Vyndamax® Capsules as the treatment of transthyretin amyloid cardiomyopathy&#xD;
      during 10 years under the setting of routine practice in Korea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of Adverse Events (AEs)</measure>
    <time_frame>Baseline through 6 months of treatment</time_frame>
    <description>The primary interest of this study is the incidence of AEs investigated during administration period and within 28 days after discontinuation of Vyndamax® Capsules. Incidence of AEs, 95% confidence interval and the number of AEs will be presented.&#xD;
Serious AEs/ADRs, unexpected AEs/ADRs, unexpected serious AEs/ADRs will be summarized separately table.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the New York Heart Association (NYHA) class at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 6 Minute Walk Distance (6MWD) at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment by investigator at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ATTR-CM (Transthyretin Amyloid Cardiomyopathy)</condition>
  <arm_group>
    <arm_group_label>Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vyndamax (tafamidis 61mg)</intervention_name>
    <description>As prescribed in real world practice</description>
    <arm_group_label>Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)</arm_group_label>
    <other_name>Tafamadis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be performed in patients who have received at least 1 dose of Vyndamax&#xD;
        Capsules for the following indications as per local product label.(Treatment of the&#xD;
        cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in&#xD;
        adults to reduce cardiovascular mortality and cardiovascular-related hospitalization)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        *Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for inclusion in&#xD;
        the study:&#xD;
&#xD;
          -  1. Adult patients with the cardiomyopathy of wild type or hereditary&#xD;
             transthyretin-mediated amyloidosis (ATTR-CM)&#xD;
&#xD;
          -  2. Patients to whom Vyndamax® Capsules is prescribed for the treatment of the&#xD;
             cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)&#xD;
&#xD;
          -  3. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient (or a legally acceptable representative) has been informed of all&#xD;
             pertinent aspects of the study.&#xD;
&#xD;
               -  Exclusion criteria&#xD;
&#xD;
        Patients meeting any of the following criteria will not be included in the study according&#xD;
        to the local product label:&#xD;
&#xD;
          -  1. Patient with hypersensitivity or case history to tafamidis or to any of the&#xD;
             excipients in the product&#xD;
&#xD;
          -  2. This product contains sorbitol (E420). Patients with rare hereditary problems of&#xD;
             fructose intolerance should not take this medicine.&#xD;
&#xD;
          -  3. Patient who has a contraindication to Vyndamax® Capsules according to the approved&#xD;
             local product label&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B3461080</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

